The compound 2' -fluoro-2',3'-dideoxyarabinosyladenine (F-ddA; Fig. 1 ) possesses preclinical anti-human immunodeficiency virus (HIV) activity both in vitro and in vivo (Boyle et al., 1995; Ruxrungtham et al., 1996) . In addition, it is significantly more stable towards metabolic and acid-induced degradation than non-fluorinated purine dideoxynucleosides (Marquez et al., 1987; Masood et al., 1990; Hitchcock et al., 1990) . As a consequence, a clinical trial ofF-ddA was begun at the NIH (Bethesda, Md., USA) during 1996.
HIV resistance and cross-resistance have become items of general concern in AIDS therapy (Larder et al., 1990; D'Aquila, 1994) . This topic has been reviewed for nucleoside reverse transcriptase (RT) inhibitors (Smith et al., 1994; Mayers, 1996) , non-nucleoside reverse transcriptase inhibitors (NNRTI) (Kilby & Saag, 1994; De Clercq, 1995) and for the newly-emerging protease inhibitors (Otto et al., 1993; Mellors et al., 1995) . Significant progress has been made in correlating the development of resistance with various drug-induced RT mutations (Mellors et al., 1995) . While the relationship between drug resistance and clinical disease progression for most anti-HIV drugs is not clear at present (Richman, 1993 (Richman, , 1994 Erice & Balfour, 1994) , it is obvious that HIV drug resistance is both complex and multi-faceted, with some resistance-inducing RT mutations causing resensitization d In this study, a virus strain was defined as resistantif potency is decreased >5-fold relative to the sensitive AO12151 strain.
to other drugs (De Clercq, 1994 , 1995 D'Aquila, 1994) . The present investigation reports the activity ofF-ddA against a number of drug-resistant clinical isolates and laboratory-generated resistant HIV strains. Comparative data for the corresponding sensitive (pre-treatment) strains, as well as for HIV-1 clades A-E, are also described, The assay systems used [the patient-HIV isolate/phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cell (PBMC) test system (Japour et a!., 1993; Mayers et a!., 1994) and the HIV-1/MT-2 and MT-4 systems (Weislow et a!., 1990) ] have been described previously. The significant differences between patient isolates and laboratory HIV strains have been discussed previously (Larder eta!., 1990) . Table 1 describes data in the ACTG/DoD PBMCbased assay system (Japour et a!., 1993) and compares the anti -HIV potency of F-ddA to ddI and zidovudine (AZT) using several clinical HIV isolates that are resistant to one or both of the latter two drugs. ddC was included as a positive control. Emphasis was placed on ddI -resistant HIV strains since ddI, like F-ddA, is a dideoxypurine analogue with a similar active metabolite (ddATP versus FddATP). HIV strains A012(S) and A012(R) as well as A018(S) and A018(R) were isolated from patients prior to and after zidovudine therapy (Larder et al., 1989) . A018(R) contains RT mutations at positions 67, 70, 215 and 219. The other patient isolates were obtained as described earlier (Japour et a!., 1993) .
Against the zidovudine-resistant strains A012(R) and 108 A018(R), zidovudine showed 50-to 250-fold potency decreases. No significant decrease in drug sensitivity was noted for F-ddA, ddI or ddC against these viruses. The degree of ddI resistance in the five ddI -resistant clinical isolates shown in Table 1 was relatively low when compared with the zidovudine resistance seen in the A012 and A018 strains. An average ddI potency decrease of7.6-fold was observed in these five virus strains [relative to the potency of ddI against the most sensitive wild-type virus, A012(S)]. However, only 3.8-fold resistance was noted relative to the A018(S) strain. Against non-resistant HIV strains in PBMC, F-ddA was several-fold less potent than ddI. The magnitude of this difference, however, was a function of the host cell type (see Tables 1 and 2 ). F-ddA showed essentially no potency loss against these five ddIresistant viruses. F-ddA exhibited no toxicity to PHAstimulated PBMC after 7 days exposure at concentrations less than 42 f-lM (data not shown). F-ddA sensitivity studies were also carried out using MT-4 host cells (Table 2) . Zidovudine showed a greater than 300-fold potency reduction in the zidovudine-resistant A018 strain while F-ddA potency was again unchanged. Comparing compound activity against the sensitive lIIB strain and the NNRTI-resistant strain A17 (Merck pyridone-derived with mutations at positions 103 and 181), the potencies of F-ddA and zidovudine were undiminished, while nevirapine, the negative control, was inactive against the A17 strain.
A comparison of F-ddA with additional anti-HIV drugs was conducted using zidovudine-and NNRTIresistant HIV in MT-2 host cells (Table 2) . Only a two-to fourfold decrease in potency was noted for F-dclA, ddC, ddI and 3TC in the zidovudine-resistant A018(R) strain, while zidovudine changed from highly potent to inactive. Except for the negative control, TIBO, the compounds studied in the A17/MT-2 system showed limited potency decreases (two to threefold) relative to a corresponding sensitive strains (Table 2 ). The F-dcIA potency difference in MT-4 and MT~2 host cells (Table 2; De Clercq, 1992; Driscoll et al., 1996) are attributed to experiments being conducted in different laboratories under somewhat different conditions. A study is in progress to select and characterize F-dcIA-resistant HIV-1 strains. Investigations studying HIV-1 strains characteristic of major geographic regions (clades) have determined how different surface proteins affect vaccine utility (e.g. Moore et al., 1996) . There is little reported information on whether clade type affects the activity or potency of anti-HIV drugs (Halliday et al., 1996) . We compared the anti-HIV potencies of F-dcIA and zidovudine against clades A-E in PBMCs (Table 3) . Both drugs possessed excellent activity at concentrations producing no cellular toxicity. While zidovudine is much more potent than F-dcIA in this test system, the difference is a specific property of the host cell system and is related to the unusually high levels Antiviral Chemistry &Chemotherapy 8(2) of thymidine kinase produced in mitogen-activated PBMCs (Gao et al., 1993 (Gao et al., , 1994 . ddI, like F-dclA, is much less potent than zidovudine in the PHA-PBMC/HIV-1 system (De Clercq, 1992) . This difference, however, is not reflected in the daily clinical doses of zidovudine and ddI, which are similar. In summary, F-ddA, a dideoxypurine nucleoside anti-HIV drug which recently entered clinical trial, remains effective against both clinical and laboratory-derived strains resistant to a variety of anti-HIV drugs. Comparable anti-HIV activities, but not potencies, were observed with F-ddA and zidovudine against HIV-l clades A-E in stimulated PEMe.
